Proposal

MNC Capital Submits Proposal to Acquire Vista Outdoor for $35.00 Per Share in Cash

Retrieved on: 
Friday, March 1, 2024

We are writing to express our strong interest in acquiring all the outstanding shares of Vista Outdoor Inc. (“Vista” or the “Company”) for a purchase price per share of $35.00 in cash (the “Transaction”).

Key Points: 
  • We are writing to express our strong interest in acquiring all the outstanding shares of Vista Outdoor Inc. (“Vista” or the “Company”) for a purchase price per share of $35.00 in cash (the “Transaction”).
  • The proposed price offers a substantial premium to Vista’s share price, which already reflects a takeover premium.
  • Given Vista’s share price is currently trading close to its 52-week high, our proposal also reflects a highly attractive value overall to Vista’s shareholders.
  • The Board is currently reviewing the proposal consistent with its fiduciary duties, in consultation with our legal and financial advisors.

Reticulate Micro Continues Management Hires with Key Business Development and Marketing Appointments  

Retrieved on: 
Tuesday, February 20, 2024

PALM BAY, Fla., Feb. 20, 2024 /PRNewswire/ -- Reticulate Micro, Inc. ("Reticulate Micro," "Reticulate" or the "Company"), a defense technology company dedicated to delivering trusted and resilient communications over any transport and in any environment, has announced key management appointments to support the company's business development and marketing functions.  

Key Points: 
  • PALM BAY, Fla., Feb. 20, 2024 /PRNewswire/ -- Reticulate Micro, Inc. ("Reticulate Micro," "Reticulate" or the "Company"), a defense technology company dedicated to delivering trusted and resilient communications over any transport and in any environment, has announced key management appointments to support the company's business development and marketing functions.
  • At Reticulate Micro, he serves as the lead for defense tactical communications, redefining connective resiliency through quantum-protected, open platform video compression management.
  • On the marketing side, Reticulate has announced that Anne Wainscott-Sargent has joined as senior director, Marketing and Communications.
  • An award-winning writer and communicator for disruptive deep tech industries, Wainscott-Sargent leads marketing, PR and brand communications for Reticulate Micro.

New Collaboration with Phius Expands Passive Building Education at Greenbuild 2024

Retrieved on: 
Thursday, February 15, 2024

NEW YORK, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Informa Connect, the U.S. Green Building Council (USGBC), and Phius announced a collaboration bringing programming from leading passive building conference, PhiusCon, into the 2024 Greenbuild International Conference + Expo. This collaboration builds on a shared commitment to accelerate progress toward decarbonization of our built environment by bringing passive building experts, strategies, and solutions to the world's largest gathering of the green building industry.

Key Points: 
  • Informa Connect, the U.S. Green Building Council (USGBC), and Phius announced a collaboration bringing programming from leading passive building conference, PhiusCon, into the 2024 Greenbuild International Conference + Expo
    NEW YORK, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Informa Connect, the U.S. Green Building Council (USGBC), and Phius announced a collaboration bringing programming from leading passive building conference, PhiusCon, into the 2024 Greenbuild International Conference + Expo.
  • Phius is a leader in climate-specific zero-energy and passive house design, climate-positive solutions, and building science.
  • Phius passive building principles are rooted in adaptability and resilience – an increasingly important facet with the rise of climate-related weather events and grid outages.
  • The Phius/Greenbuild collaboration highlights the synergies between passive and green building strategies to reduce the strain on resources while improving livability.

USABC AWARDED $60 MILLION FOR PRE-COMPETITIVE, VEHICLE-RELATED ADVANCED BATTERY RESEARCH AND DEVELOPMENT FROM US DEPARTMENT OF ENERGY

Retrieved on: 
Wednesday, January 31, 2024

Southfield, Mich., Jan. 31, 2024 (GLOBE NEWSWIRE) -- The U.S. Department of Energy (DOE) announced the United States Advanced Battery Consortium LLC (USABC) will receive $60 million for pre-competitive, vehicle-related advanced battery research and development that addresses critical priorities for the next phase of widescale electric vehicle (EV) commercialization.

Key Points: 
  • Southfield, Mich., Jan. 31, 2024 (GLOBE NEWSWIRE) -- The U.S. Department of Energy (DOE) announced the United States Advanced Battery Consortium LLC (USABC) will receive $60 million for pre-competitive, vehicle-related advanced battery research and development that addresses critical priorities for the next phase of widescale electric vehicle (EV) commercialization.
  • USABC is a subsidiary of the United States Council for Automotive Research LLC (USCAR).
  • In support of its mission, USABC has developed mid- and long-term goals to guide its projects and measure its progress.
  • “We are excited to strategically expand our priorities from the last agreement to advance battery technology development,” said Dr. Steven Przesmitzki, executive director of USCAR.

MTF Biologics Awards 2023 Grants for Innovation in Allograft Translational Research

Retrieved on: 
Monday, January 22, 2024

“MTF Biologics is proud of our long-standing commitment to supporting the scientific and patient communities through our allograft innovation grants,” said Joe Yaccarino, President and CEO of MTF Biologics.

Key Points: 
  • “MTF Biologics is proud of our long-standing commitment to supporting the scientific and patient communities through our allograft innovation grants,” said Joe Yaccarino, President and CEO of MTF Biologics.
  • “These grants advance the science of allograft tissue transportation and support MTF Biologics’ dedication to saving and healing lives.
  • We congratulate all of this year's recipients and look forward to the results of their crucial work which will positively impact lives around the world.”
    Innovation in Allograft Translational Research Grants fund translational and clinical research in the fields of allograft transplantation and allograft science.
  • Hans Burchardt Impact Awardee” for the awarded grant with the highest potential clinical impact.”
    Letters of Intent are now being accepted for the 2024 MTF Biologics Innovation in Allograft Translational Research Grants Program.

International Association for the Study of Lung Cancer (IASLC) and Lung Cancer Research Foundation (LCRF) Announce Request for Proposals

Retrieved on: 
Thursday, January 11, 2024

NEW YORK, Jan. 11, 2024 /PRNewswire-PRWeb/ -- The Lung Cancer Research Foundation announced today that, in partnership with the International Association for the Study of Lung Cancer, submissions are being accepted for the $2.5 million, four-year award, titled IASLC-LCRF Team Science Research Grant on Advancing Therapies Towards Curing Oncogenic-Driven Lung Cancers.

Key Points: 
  • NEW YORK, Jan. 11, 2024 /PRNewswire-PRWeb/ -- The Lung Cancer Research Foundation announced today that, in partnership with the International Association for the Study of Lung Cancer, submissions are being accepted for the $2.5 million, four-year award, titled IASLC-LCRF Team Science Research Grant on Advancing Therapies Towards Curing Oncogenic-Driven Lung Cancers.
  • It is expected that a program of correlative, translational research will be proposed that will enhance the understanding of these oncogenic-driven lung cancers.
  • "Soliciting research proposals that seek to cure oncogenic-driven lung cancer is a step in the right direction to improve survivorship."
  • More details about the Request for Proposal, along with eligibility, requirements, and deadlines can be found at LCRF.org/FundingOpportunities.

International Association for the Study of Lung Cancer (IASLC) and Lung Cancer Research Foundation (LCRF) Announce Request for Proposals

Retrieved on: 
Thursday, January 11, 2024

NEW YORK, Jan. 11, 2024 /PRNewswire/ -- The Lung Cancer Research Foundation announced today that, in partnership with the International Association for the Study of Lung Cancer, submissions are being accepted for the $2.5 million, four-year award, titled IASLC-LCRF Team Science Research Grant on Advancing Therapies Towards Curing Oncogenic-Driven Lung Cancers.

Key Points: 
  • NEW YORK, Jan. 11, 2024 /PRNewswire/ -- The Lung Cancer Research Foundation announced today that, in partnership with the International Association for the Study of Lung Cancer, submissions are being accepted for the $2.5 million, four-year award, titled IASLC-LCRF Team Science Research Grant on Advancing Therapies Towards Curing Oncogenic-Driven Lung Cancers.
  • It is expected that a program of correlative, translational research will be proposed that will enhance the understanding of these oncogenic-driven lung cancers.
  • "Soliciting research proposals that seek to cure oncogenic-driven lung cancer is a step in the right direction to improve survivorship."
  • More details about the Request for Proposal, along with eligibility, requirements, and deadlines can be found at LCRF.org/FundingOpportunities.

TDCX Inc. Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Remaining Outstanding Class A Ordinary Shares of the Company

Retrieved on: 
Wednesday, January 3, 2024

A copy of the Proposal Letter is attached hereto as Exhibit A.

Key Points: 
  • A copy of the Proposal Letter is attached hereto as Exhibit A.
  • The Company has formed a special committee of the Board, comprised solely of independent and disinterested directors, to consider the Proposal Letter and the Proposed Transaction and make recommendation to the Board.
  • The Board expects that the special committee will retain independent legal and financial advisors to assist in the review of the Proposed Transaction.
  • The Company cautions that the Board has just received the Proposal Letter and has not made any decisions with respect to the Proposal Letter and the Proposed Transaction.

LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences

Retrieved on: 
Wednesday, December 6, 2023

SHANGHAI, China and PRINCETON, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that its Board of Directors (the “Board”) unanimously determined not to pursue the unsolicited proposal from Concentra Biosciences, LLC to acquire 100% of the equity of LianBio for $4.30 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of LianBio’s programs (the “Proposal”).

Key Points: 
  • SHANGHAI, China and PRINCETON, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that its Board of Directors (the “Board”) unanimously determined not to pursue the unsolicited proposal from Concentra Biosciences, LLC to acquire 100% of the equity of LianBio for $4.30 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of LianBio’s programs (the “Proposal”).
  • After careful review and consideration, the Board unanimously concluded that the Proposal undervalues the Company and is not in the best interests of LianBio or its shareholders.

LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

Retrieved on: 
Friday, December 1, 2023

SHANGHAI, China and PRINCETON, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today confirmed that Concentra Biosciences, LLC (“Concentra”), of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal (the “Proposal”) to acquire 100% of the equity of LianBio.

Key Points: 
  • SHANGHAI, China and PRINCETON, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today confirmed that Concentra Biosciences, LLC (“Concentra”), of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal (the “Proposal”) to acquire 100% of the equity of LianBio.
  • According to the Schedule 13D filed on November 30, 2023 with the U.S. Securities and Exchange Commission (“SEC”) disclosing the Proposal, Tang Capital1 is currently approximately an 8.6% shareholder of LianBio.
  • The Proposal consists of $4.30 in cash per share plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of LianBio’s programs.
  • The Board is committed to acting in the best interests of all shareholders, consistent with its fiduciary duties.